mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes
- Merav Fraenkel1,
- Mali Ketzinel-Gilad1,
- Yafa Ariav1,
- Orit Pappo2,
- Melis Karaca3,
- Julien Castel3,
- Marie-France Berthault3,
- Christophe Magnan3,
- Erol Cerasi1,
- Nurit Kaiser1 and
- Gil Leibowitz1
- 1Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 2Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- 3Laboratoire de Physiopathologie de la Nutrition, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Universiteì Paris, Paris, France
- Address correspondence and reprint requests to Gil Leibowitz, MD, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, P.O. Box 12000, Jerusalem 91120. E-mail:
OBJECTIVE—Mammalian target of rapamycin (mTOR) and its downstream target S6 kinase 1 (S6K1) mediate nutrient-induced insulin resistance by downregulating insulin receptor substrate proteins with subsequent reduced Akt phosphorylation. Therefore, mTOR/S6K1 inhibition could become a therapeutic strategy in insulin-resistant states, including type 2 diabetes. We tested this hypothesis in the Psammomys obesus (P. obesus) model of nutrition-dependent type 2 diabetes, using the mTOR inhibitor rapamycin.
RESEARCH DESIGN AND METHODS—Normoglycemic and diabetic P. obesus were treated with 0.2 mg · kg−1 · day−1 i.p. rapamycin or vehicle, and the effects on insulin signaling in muscle, liver and islets, and on different metabolic parameters were analyzed.
RESULTS—Unexpectedly, rapamycin worsened hyperglycemia in diabetic P. obesus without affecting glycemia in normoglycemic controls. There was a 10-fold increase of serum insulin in diabetic P. obesus compared with controls; rapamycin completely abolished this increase. This was accompanied by weight loss and a robust increase of serum lipids and ketone bodies. Rapamycin decreased muscle insulin sensitivity paralleled by increased glycogen synthase kinase 3β activity. In diabetic animals, rapamycin reduced β-cell mass by 50% through increased apoptosis. Rapamycin increased the stress-responsive c-Jun NH2-terminal kinase pathway in muscle and islets, which could account for its effect on insulin resistance and β-cell apoptosis. Moreover, glucose-stimulated insulin secretion and biosynthesis were impaired in islets treated with rapamycin.
CONCLUSIONS—Rapamycin induces fulminant diabetes by increasing insulin resistance and reducing β-cell function and mass. These findings emphasize the essential role of mTOR/S6K1 in orchestrating β-cell adaptation to hyperglycemia in type 2 diabetes. It is likely that treatments based on mTOR inhibition will cause exacerbation of diabetes.
- FFA, free fatty acid
- IRS, insulin receptor substrate
- JNK, c-Jun NH2-terminal kinase
- KRBH, Krebs-Ringer bicarbonate HEPES buffer
- mTOR, mammalian target of rapamycin
- S6K1, S6 kinase 1
- SAPK, stress-activated protein kinase
- TORC1, rapamycin-sensitive complex with the regulatory-associated protein of mTOR (raptor)
- TORC2, rapamycin-resistant complex with rapamycin-insensitive companion of mTOR (rictor)
- TUNEL, transferase-mediated dUTP nick-end labeling
- Received July 5, 2007.
- Accepted December 24, 2007.